Tamara Maes
Fortuna: 18 M $ al 30/06/2026
Fortuna: 18 M $ al 30/06/2026
Tamara Maes was the founder of Oryzon Genomics SA, holding the title of First Deputy Chairman from 2000 to 2025.
Current jobs include Director at Mendelion Lifesciences SL, Member at Alzheimers Drug Discovery Foundation since 2016, and Scientific Coordinator at Oncnosis Pharma AIE.
Education includes a doctorate from Ghent University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ORYZON GENOMICS SA 6,24 % | 26/06/2025 | 4.985.060 ( 6,24 % ) | 18 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
Oncnosis Pharma AIE | Corporate Officer/Principal | - |
Mendelion Lifesciences SL
Mendelion Lifesciences SL Engineering & ConstructionIndustrial Services Constructs commercial buildings | Director/Miembro de la Junta | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology Operates as a research organisation | Corporate Officer/Principal | 01/01/2016 |
| Empresas | Cargo | Fin |
|---|---|---|
| ORYZON GENOMICS S.A. | Fundador | 28/02/2025 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Oryzon Genomics SA
Oryzon Genomics SA BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops epigenetics-based therapeutics | Health Technology |
Ghent University
Ghent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology Operates as a research organisation | Health Technology |
Oncnosis Pharma AIE | |
Mendelion Lifesciences SL
Mendelion Lifesciences SL Engineering & ConstructionIndustrial Services Constructs commercial buildings | Industrial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.